• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Argatroban Injection

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Argatroban Injection

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Heparin is the most commonly used anticoagulant for patients requiring immediate anticoagulation therapy. Heparin-induced thrombocytopenia (HIT) has an immunologic basis and is commonly associated with venous thrombosis. The availability of direct thrombin inhibitors has assisted physicians in managing this disorder.

    HIT is an immunoglobulin-mediated adverse drug reaction that is characterized by platelet activation, thrombocytopenia, and a high risk of thrombotic complications among patients receiving or who have recently received heparin. HIT is one of the most important immunologic drug reactions.

    Thrombocytopenia is usually mild to moderate, with platelet counts ranging from 20 to 150 x 109/L. Similarly, a fall in platelet count of 50% or more that begins later than 5 days after the start of heparin therapy, but with the platelet count still above the usual threshold for thrombocytopenia (150 x 109/L), should also raise the suspicion of HIT.13 By comparison, thrombocytopenia induced by sulfa drugs and quinine is typically much more severe. (from uspharmacist.com)

    Clinical Results

    The conclusion that Argatroban is an effective treatment for heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) is based upon the data from a historically controlled efficacy and safety study (Study 1) and a follow-on efficacy and safety study (Study 2). These studies were comparable with regard to study design, study objectives, dosing regimens as well as study outline, conduct, and monitoring.

    In these studies, 568 adult patients were treated with Argatroban and 193 adult patients made up the historical control group. Patients were required to have a clinical diagnosis of heparin-induced thrombocytopenia, either without thrombosis (HIT) or with thrombosis (HITTS) and be males or non-pregnant females between the age of 18 and 80 years old.

    Patients with documented unexplained aPTT greater than 200% of control at baseline, documented coagulation disorder or bleeding diathesis unrelated to HITTS, a lumbar puncture within the past 7 days or a history of previous aneurysm, hemorrhagic stroke, or recent thrombotic stroke, within the past 6 months, unrelated to HITTS were excluded from these studies.

    The primary efficacy analysis was based on a comparison of event rates for a composite endpoint that included death (all causes), amputation (all causes) or new thrombosis during the treatment and follow-up period (study days 0 to 37). Secondary analyses included evaluation of the event rates for the components of the composite endpoint as well as time-to-event analyses.

    A categorical analysis showed a significant improvement in the composite outcome in patients with HIT and HITTS treated with Argatroban versus those in the historical control group.

    Side Effects

    Side effects may include:

    • Dyspnea
    • Hypotension
    • Fever
    • Diarrhea
    • Sepsis
    • Cardiac Arrest
    • Nausea
    • Ventricular tachycardia
    • Pain
    • Urinary tract infection
    • Vomiting
    • Infection
    • Pneumonia
    • Atrial fibrillation
    • Coughing
    • Abnormal renal function
    • Abdominal pain
    • Cerebrovascular disorder

    There were hemorrhagic events of both minor and major status in the following areas:

    • Major:

    • Gastrointestinal
    • Genitourinary and hematuria
    • Decrease hemoglobin/hematocrit
    • Multisystem hemorrhage and DIC
    • Limb and BKA stump

      Minor:

    • Gastrointestinal
    • Genitourinary and hematuria
    • Decrease in hemoglobin and hematocrit
    • Groin
    • Hemoptysis
    • Brachial

    Mechanism of Action

    Argatroban is a direct thrombin inhibitor that reversibly binds to the thrombin active site. It does not require the co-factor antithrombin III for antithrombotic activity. Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation.

    Argatroban is highly selective for thrombin with an inhibitory constant of 0.04 uM. At therapeutic concentrations, argatroban has little or no effect on related serine proteases.

    Argatroban is capable of inhibiting the action of both free and clot-associated thrombin. It does not interact with heparin-induced antibodies. (from fda.gov)

    Additional Information

    It is not known whether this drug is excreted in human milk. Because many drugs are, and because of the potential for nursing-infant harm, a decision should be made whether to discontinue nursing or discontinue the drug.

    Approval Date: 2000-06-01
    Company Name: Texas Biotechnology Corporation, SmithKline Beecham
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing